<DOC>
	<DOC>NCT00825643</DOC>
	<brief_summary>This study is conducted in Europe, North America and Asia. The aim of this observational study is to evaluate the safety and effectiveness while using Levemir速 once daily in combination with oral antidiabetic drugs in type 2 diabetics during 24 weeks under normal clinical practice. Data from the NN304-3573 study (NCT00740519) will be pooled with data from this study and reported together in the final study report for this study.</brief_summary>
	<brief_title>Observational Study to Evaluate the Safety of Levemir速 in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>After the participating physician's decision has been made to initiate oncedaily Levemir速 therapy, any patient with Type 2 diabetes who is currently treated with diet, exercise and one or more OADs can be offered to participate Current treatment with insulin Known or suspected allergy to Levemir速 or excipients Children below the age of 6 years Females of childbearing potential who are pregnant, breastfeeding or intend to become pregnant within the next 6 months or are not using adequate contraceptive methods (contraceptive measures as required by local law or practice)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>